0000000000012686

AUTHOR

Steffen Schneider

showing 6 related works from this author

Impact of prehospital delay on mortality in patients with acute myocardial infarction treated with primary angioplasty and intravenous thrombolysis.

2001

Abstract Background In patients with acute myocardial infarction treated with thrombolysis, longer times to treatment are associated with increasingly worse clinical outcome. This relation may be different for treatment with primary angioplasty. Methods We analyzed the pooled data of the German acute myocardial infarction registries Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) and Myocardial Infarction Registry (MIR) to determine the influence of prehospital delays on hospital mortality rates. Primary angioplasty was performed in 1063 patients and thrombolysis in 7552 patients. Results In patients treated with thrombolysis, in-hospital time to treatment was constantly 3…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentTime to treatmentPrimary angioplastyMyocardial InfarctionStatistics NonparametricInternal medicineFibrinolysismedicineHumansIn patientThrombolytic TherapyMyocardial infarctionHospital MortalityProspective StudiesRegistriesChemotherapyChi-Square Distributionbusiness.industryMortality rateThrombolysisMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeCardiologyFemaleCardiology and Cardiovascular MedicinebusinessAngioplasty BalloonAmerican heart journal
researchProduct

Predictors of early scaffold thrombosis: results from the multicenter prospective German-Austrian ABSORB RegIstRy.

2018

BACKGROUND In randomized clinical trials, the risk of thrombotic events with the absorb bioresorbable vascular scaffold (BVS) was significantly higher than with metallic drug-eluting stents. We evaluated predictors of scaffold thrombosis in the large-scale, multicenter German-Austrian ABSORB RegIstRy. METHODS AND RESULTS 3178 patients with treatment of 4252 lesions using 5020 scaffolds were included. Follow-up rate at 6 months was 97.4%. Forty-five (1.42%) patients experienced definite/probable scaffold thrombosis during follow-up. Multiple regression analysis showed implantation of absorb BVS in bifurcation lesions [odds ratio (OR): 4.43; 95% confidence interval (CI): 1.69-11.59; P=0.0024]…

Target lesionMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentClinical Decision-MakingCoronary Artery Disease030204 cardiovascular system & hematologyRevascularizationRisk Assessment03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionRisk FactorsGermanyAbsorbable ImplantsMedicineHumans030212 general & internal medicineMyocardial infarctionProspective StudiesRegistriesAgedbusiness.industryIncidence (epidemiology)Coronary ThrombosisPatient SelectionGeneral MedicineOdds ratioMiddle AgedDebulkingmedicine.diseaseThrombosisConfidence intervalSurgeryTreatment OutcomeAustriaFemaleCardiology and Cardiovascular MedicinebusinessCoronary artery disease
researchProduct

Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with …

2015

Abstract Background Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent thrombosis. The development of bioresorbable scaffolds (BRSs) promises advantages over metal stents due to complete biodegradation within 2–4 years. Theoretically, since vessel scaffolding is temporary and no permanent implant remains in the vessel, BRSs, as opposed to metal stents, once degraded would no longer be potential triggers for stent-related adverse events or side e…

medicine.medical_specialtyPercutaneousmedicine.medical_treatmentMedizin030204 cardiovascular system & hematologyRevascularizationlaw.inventionCohort StudiesCoronary artery disease03 medical and health sciences0302 clinical medicineRandomized controlled triallawGermanyAbsorbable ImplantsmedicineHumansEverolimusProspective StudiesRegistries030212 general & internal medicineMyocardial infarctionEverolimusbusiness.industryCoronary StenosisPercutaneous coronary interventionDrug-Eluting StentsGeneral Medicinemedicine.diseaseSurgeryStenosisTreatment OutcomeResearch DesignAustriaCardiology and Cardiovascular Medicinebusinessmedicine.drugCardiovascular Revascularization Medicine
researchProduct

Gender differences in acute myocardial infarction in the era of reperfusion (the MITRA registry).

2002

There is conflicting information about gender differences in presentation, treatment, and outcome after acute ST elevation myocardial infarction (STEMI) in the era of thrombolytic therapy and primary percutaneous coronary intervention. From June 1994 to January 1997, we enrolled 6,067 consecutive patients with STEMI admitted to 54 hospitals in southwest Germany in the Maximal Individual TheRapy of Acute myocardial infarction (MITRA), a community-based registry. Women were 9 years older than men, more often had hypertension, diabetes mellitus, and congestive heart failure, and had a history of previous myocardial infarction less often. Women had a longer prehospital delay (45 minutes), had a…

Malemedicine.medical_specialtyEmergency Medical Servicesmedicine.medical_treatmentMyocardial InfarctionInfarctionAngina PectorisAnginaReperfusion therapySex FactorsInternal medicineGermanymedicineHumansThrombolytic TherapyMyocardial infarctionHospital MortalityProspective StudiesRegistriesAgedHeart Failurebusiness.industryPercutaneous coronary interventionThrombolysisOdds ratioMiddle Agedmedicine.diseaseSurvival AnalysisHeart failureCardiologyFemaleCardiology and Cardiovascular MedicinebusinessThe American journal of cardiology
researchProduct

Primär-Dilatation versus Thrombolyse bei Patienten mit akutem Myokardinfarkt, die nicht in randomisierte Studien eingeschlossen wurden

1999

Die randomisierten Studien zum Vergleich der Thrombolyse und der Primar-Dilatation beim akuten Myokardinfarkt schlossen keine Patienten mit Linksschenkelblock, nichtdiagnostischem ersten Elektrokardiogramm, einer Prahospitalzeit von ≥ 12 h oder einer unbekannten Prahospitalzeit ein. Im klinischen Alltag werden jedoch haufig solche Patienten mittels Thrombolyse oder Primar-Dilatation behandelt. Um diese Patientengruppen zu beschreiben und den Einflus der Lyse und der Primar-Dilatation zu vergleichen, untersuchten wir die Daten aus der “Maximale Individuelle Optimierte Therapie beim Akuten Myokardinfarkt” (MITRA)-Studie. Bei 737 von 3308 (22,3 %) mittels Primar-Dilatation oder Lyse behandelte…

Gynecologymedicine.medical_specialtybusiness.industrymedicineMyocardial diseaseCardiology and Cardiovascular MedicinebusinessCoronary heart diseaseZeitschrift f�r Kardiologie
researchProduct

Primary angioplasty versus intravenous thrombolysis in acute myocardial infarction: can we define subgroups of patients benefiting most from primary …

2001

Abstract OBJECTIVES We sought to determine the effectiveness of primary angioplasty compared with thrombolysis in clinical practice. BACKGROUND In clinical practice, primary angioplasty for the treatment of acute myocardial infarction (AMI) has not yet been proven more effective than intravenous thrombolysis, nor have subgroups of patients been identified who would perhaps benefit from primary angioplasty. METHODS The pooled data of two AMI registries—the Maximal Individual TheRapy in Acute myocardial infarction (MITRA) study and the Myocardial Infarction Registry (MIR)—were analyzed. A total of 9,906 lytic-eligible patients with AMI, with a pre-hospital delay of ≤12 h, were treated with ei…

medicine.medical_specialtyUnivariate analysisbusiness.industrymedicine.medical_treatmentAbsolute risk reductionThrombolysisOdds ratiomedicine.diseaseConfidence intervalInternal medicineConcomitantAngioplastyCardiologyMedicineMyocardial infarctionbusinessCardiology and Cardiovascular MedicineJournal of the American College of Cardiology
researchProduct